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Case Report 
Introduction
Familial hypocalciuric hypercalcemia (FHH) is one of the
calcium homeostasis disorders characterised by mild to
moderate hypercalcemia, generally accompanied with no
symptoms, inherited as an autosomal dominant trait.1,2
Surgery is not indicated for this entity. In 1993, it was
reported that the cause of FHH was a heterozygous inac-
tivating mutation in the calcium sensing receptor (CaSR)
gene.3 Since then, a large number of inactivating muta-
tions in the CaSR gene associated with FHH have been
reported.4 Moreover, it is suggested that mutations in
genes in at least two other distinct locations (19p and
19q) are causative of FHH.5,6 In respect to the degree of
hypercalcemia, the clinical features of FHH are similar to
those of mild primary hyperparathyroidism (PHPT). Thus,
differential diagnosis between FHH and PHPT is clini-
cally important, although it may be somewhat difficult.
Here, we show the very rare case of a patient with FHH
associated with parathyroid adenoma causing PHPT and
papillary thyroid carcinoma, and describe the clinical fea-
tures of this rare but clinically important association.
Case report
A 76-year-old Japanese man visited a local hospital 
complaining of weight loss. For a whole body exami-
nation a 18F-fluoro-2-deoxyglucose positron emission
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tomography scan was performed, revealing a focus with
increased uptake in the right lobe of the thyroid gland.
Thus, he was referred to our hospital in June 2006. 
He experienced repeated episodes of urolithiasis. His son
had a history of asymptomatic hypercalcemia. Ultra-
sonography (US) of the neck showed a 27 × 20 mm 
nodule in the right and a 7 × 5 mm nodule in the left 
lobe of the thyroid gland. Laboratory data of the patient
are shown in Table 1. Serum concentration of calcium,
intact PTH and ionised calcium was increased. Fractional
excretion of calcium (FECa) was below 0.01. Thyroid
function was normal. The bone mineral density of the
lumbar spines and femoral neck showed 1.300 g/cm2
(T score, 0.8; Z score, 2.3) and 0.876 g/cm2 (T score, −0.5;
Z score, 0.8), respectively. Bone turnover markers, urinary
type I collagen cross-linked N-telopeptides (NTx) and
serum bone-specific alkaline phosphatase (BAP) were
within normal range. Computed tomography (CT) scans
of the neck revealed a tumour posterior to the left lobe 
of the thyroid gland, suggesting left lower parathyroid
enlargement (Figure 1A), as well as thyroid tumours in
both lobes. 99mTc-sestamibi (MIBI) parathyroid scintigra-
phy showed MIBI accumulation in the left lower pole 
of the thyroid gland (Figure 1B). Fine needle aspiration
biopsy of the left thyroid nodule revealed papillary 
thyroid carcinoma.
The patient was suspected to have primary hyper-
parathyroidism; however, because of low FECa and his
family history, we also considered the possibility of FHH
and we therefore analysed his CaSR gene. Sequencing
analysis of the CaSR gene was approved by the ethics 
committee of Kuma Hospital, and informed consent was
obtained from all patients before samples were collected.
Sequencing analysis of the coding region of the CaSR
revealed a heterozygous novel mutation, 1-bp deletion at
A
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Figure 1. (A) Computed tomography scan showed a homoge-
neous, enhancing mass (arrow) posterior to the left lobe of the
thyroid gland. (B) MIBI scintigraphy. Early-phase (left panel) and
delayed-phase (right panel) scintigrams show a focus of uptake
in inferior aspect of the left thyroid lobe (arrow).
Table 1. Laboratory data of the proband
Preoperation Postoperation Normal
Ca (mg/dL) 11.2 10.7 8.2–10.2
Albumin (g/dL) 4.2 4.4 3.8–5.2
Ionized Ca (mEq/L) 2.96 ND 2.24–2.58
Phosphorus (mg/dL) 2.8 2.2 2.5–4.5
Intact PTH (pg/mL) 135 54 15–70
Alkaline phosphatase (IU/L) 134 184 105–340
Creatinine (mg/dL) 1.3 1.4 0.5–1.3
Cl (mEq/L) 106 101 98–110
Uric acid (mg/dL) 9.4 7.3 3.0–7.0
FECa 0.005 0.004
NTx (nmol BCE/mmol Cr) 13.7 ND 13.0–66.2
BAP (U/L) 14.2 ND 13.0–33.9
Fractional excretion of calcium (FECa) was calculated by the following formula: (urinary calcium/urinary creatinine)/(serum calcium/serum
creatinine). PTH = parathyroid hormone; NTx = N-telopeptides; BAP = serum bone-specific alkaline phosphatise; ND = not determined.
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nucleotide 3193 in exon 7 (3193delA), leading to a prema-
ture stop codon (Figure 2).
The screening study of his family members revealed
hypercalcemia with inappropriately normal intact PTH
and low FECa in his son, daughter, grandson and grand-
daughter (Table 2, Figure 3). They had the same mutation
in the CaSR gene as the patient. The CaSR gene mutation
was not detected in one of his grandsons, whose serum
calcium and PTH levels were normal.
The patient was admitted in September 2006 with a
preoperative diagnosis of papillary thyroid carcinoma
associated with FHH and PHPT. A total thyroidectomy
and central compartment lymphadenectomy were carried
out. At the same time, one enlarged parathyroid gland
behind the inferior pole of the left thyroid lobe was
resected. The upper parathyroid glands on the both side
looked normal in size and shape and were preserved in
situ in order to avoid hypoparathyroidism after surgery.
The right lower parathyroid gland could not be found
during the surgery. The parathyroid tumour was bean-
shaped, reddish-brown and 393 mg in weight, and a nor-
mal parathyroid rim was observed. Microscopically, closely
packed chief cells with enlarged hyperchromatic nuclei
were arranged in uniform sheets and cords (Figure 4). 
A rim of fat cell-rich glandular tissue was seen at the
periphery of the adenoma (Figure 4A). Four months after
surgery, his serum calcium and intact PTH level decreased,
although his serum calcium level remained mildly hyper-
calcemic (Table 1). Serum uric acid was decreased to nor-
mal range after surgery. Eighteen months after surgery,
the bone mineral density of the lumbar spines and femoral
neck showed 1.341 g/cm2 (T score, 1.1; Z score, 2.7) and
0.876 g/cm2 (T score, −0.5; Z score, 0.8), respectively.
Discussion
Clinically, it may be difficult to distinguish FHH from
PHPT. PHPT occurring in patients with FHH can be very
confusing; however, accurate diagnosis is critical, since
surgical treatment is indicated for PHPT, but not for
Table 2. Characteristics of FHH family members
Pedigree no. I-1 (proband) II-1 II-2 III-1 III-2 III-3
Ca (mg/dL) 11.2 11.5 11.5 11.5 9.6 11.2
Albumin (g/dL) 4.2 5.0 4.9 4.7 4.5 4.8
Ionized Ca (mEq/L) 2.96 ND ND ND ND ND
Phosphorus (mg/dL) 2.8 ND ND 2.8 4.7 3.0
Intact PTH (pg/mL) 135 58 64 46 28 36
FECa 0.005 0.01 0.006 0.007 ND 0.007
Genotype of the CaSR locus wt/mut wt/mut wt/mut wt/mut wt/wt wt/mut
PTH = parathyroid hormone; FECa = fractional excretion of calcium; ND = not determined; wt = wild type; mut = mutant (3193delA).
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Figure 2. Sequencing analysis of exon 7 of the CaSR gene. A het-
erozygous 3193delA (arrow) was detected in this case.
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Figure 3. Pedigree of the family with FHH. Circles and squares
represent females and males, respectively. Solid symbols repre-
sent hypercalcemia cases. The arrow indicates the proband. The
presence (+) or absence (−) of the CaSR mutation in the family
members are shown.
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FHH. The low FECa level in this patient and the family
history of asymptomatic hypercalcemia in his son were
clues to the diagnosis of FHH, and a family screening study
supported the diagnosis of FHH. The most convincing
evidence was obtained by gene analysis of CaSR in this
family. A novel CaSR gene mutation was found, which
clearly segregated five hypercalcemic individuals with low
FECa values and one normocalcemic family member.
The CaSR regulates renal tubular calcium excretion.
Patients with an inactivating mutation of the CaSR gene
display an increase in renal tubular calcium reabsorption.
Consequently, their urinary calcium excretion is reduced,
independent of PTH secretion. This probably explains
why FECa remained low in the present patient, although
he showed increased intact PTH and serum calcium lev-
els. On the other hand, it is not clear the reason why bone
turnover markers remained normal in the patient despite
an increased intact PTH level. As was seen in the present
patient, symptoms may be obscured by CaSR mutation 
in PHPT. This is consistent with a previous report that
reported that an extremely high calcium level caused only
mild symptoms in a FHH patient with parathyroid 
adenoma.7
In FHH patients, many mutations are reported in the
CaSR gene. Most of the reported mutations are a single
base substitution resulting in a missense or nonsense
mutation. These inactivating mutations cluster at the N-
terminal extracellular and transmembrane domain,4 indi-
cating that these regions are critical for the function of
CaSR protein.8 The deletion mutation in the intracellular
domain, as founded in the present family, is rare. This
novel deletion mutation leads to truncation of the intra-
cellular domain of CaSR protein. We did not perform
functional analysis of the truncated proteins; however,
the presence of the heterozygous mutation was clearly
associated with FHH phenotype in this family, speculated
that this novel mutation is an inactivating mutation of
the CaSR responsible for FHH.
Pathologically, mild hyperplasia may be present in the
parathyroid gland of FHH patients,9 however, the parathy-
roid gland from the proband showed chief cell adenoma
with a rim of normal parathyroid tissue. The serum intact
PTH level of the proband before surgery was greater than
those of the affected family members. After extirpation of
the parathyroid adenoma, the serum intact PTH level
decreased to the normal range, although the serum cal-
cium level remained mildly increased; thus, it is reason-
able to think that the proband in this case was FHH
associated with PHPT.
FHH associated with PHPT is extremely rare.7,10 Papil-
lary thyroid carcinoma is probably incidentally associated
with FHH in this patient. The association of hyperuricemia
and hyperparathyroidism has been noted.11 Indeed, hyper-
uricemia of the present patient was improved after sur-
gery. It is possible that the cause of urolithiasis in the
patient was a preoperative increase in the level of uric acid
due to PHPT. Hypercalcemia in FHH is generally asymp-
tomatic, and a consensus has evolved that parathyroidec-
tomy should be avoided in FHH. In this case, the parathyroid
adenoma was resected by central compartment lymph-
adenectomy for papillary thyroid carcinoma. Since the
patient had only mild hypercalcaemia and no hypercalci-
uria, parathyroidectomy for adenoma would be considered
unnecessary. However, since FHH was associated with
papillary thyroid carcinoma in this case and he had re-
peated urolithiasis resulting from hyperuricemia, surgery
A B
Figure 4. (A) Microscopic appearance of parathyroid tumor showing a normal rim adjacent to the tumour at low magnification. 
(B) Parathyroid adenoma at high magnification.
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was performed. Reduced CaSR expression or function may
lead to parathyroid cellular proliferation,12 and we should
consider that PHPT can occur in patients with FHH.
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